Use of GLP-1 receptor agonists, particularly liraglutide, was associated with increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) in the first year of therapy.
Patients without type 2 diabetes (T2D) or obesity exhibited the highest relative risk when exposed to GLP-1 agents.
The findings raise new safety considerations for off-label and weight management uses of GLP-1 drugs.
Further research is needed to clarify mechanisms and refine patient selection.
